

PATENT Atty. Docket No.0212-CIP-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.:

10/629,649

Confirmation No.: 6846

TC/A.U.:

Inventors:

Nigel R.A. BEELEY, et al.

1654

Filed:

July 30, 2003

Examiner: Jeffrey E. Russel

Title: METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME

TRANSMITTAL

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The following documents are enclosed herewith for your review and consideration:

- Fee Transmittal Form In duplicate (2 pages)
- Information Disclosure Statement (2 pages)
- PTO Form SB/08 (2 pages)
- Copy of PCT International Search Report (3 pages)

Respectfully submitted, AMYLIN PHARMACEUTICALS, INC.

Dated: April 4, 2005

Mi K. Kim

Registration No. 44,830

AMYLIN PHARMACEUTICALS, INC.

9360 Town Centre Drive

San Diego, CA 92121

Telephone: 858.552.2200 Facsimile: 858.552.1936

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231

4/4/05

Name of Person Mailing Raper

Signature of Person Mailing Paper

Date of Deposit

PTO/SB/17 (12-04v2) Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

work Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

	Effective on 12/08/2004. Consolidated Appropriations Act, 2005 (H.R. 4818).
FEE	TRANSMITTAL

For FY 2005 Applicant claims small entity status. See 37 CFR 1.27

OTAL	AMOUNT	OF	PAYMENT	٠	(\$)	180	-0

Complete if Known				
Application Number	10/629,649			
Filing Date	July 30, 2003			
First Named Inventor	Nigel R.A. BEELEY, et al.			
Examiner Name	Jeffrey E. RUSSEL			
Art Unit	1654			
Attorney Docket No.	0212-CIP-9			

METHOD OF PAYMEN	NT (check al	that apply)						
Check Credit	Card [Money Order	None	Other (please identify)	<u>:</u>		
Deposit Account	Deposit Account Deposit Account Number: 010535 Deposit Account Name: Amylin Pharmaceuticals							
For the above-iden	tified deposit	account, the Dire	ector is hereby	y authorized to	: (check all th	at apply)		
Charge fee(s) indicated be	elow		Charg	ge fee(s) indic	ated below, ex	cept for the filing fee	
Charge any	additional fee	(s) or underpayn	nents of fee(s) 🔽 Credi	t any overpay	ments		
WARNING: Information on th		ecome public. Cre	dit card inforn	nation should n	ot be included	on this form. Pr	ovide credit card	
information and authorization	n on P10-2038	•						
	DCU AND	EVAMINATION	I FFF6		41.			
1. BASIC FILING, SEA	FILING		SEARCH	H FEES	EXAMINA	TION FEES		
Application Type		Small Entity	5	Small Entity	<u>s</u>	mall Entity	Food Boid (\$)	
Utility	Fee (\$) 300	<u>Fee (\$)</u> 150	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)	
•			500	250	200	100		
Design	200	100	100	50	130	65		
Plant	200	100	300	150	160	80		
Reissue	300	150	500	250	600	300		
Provisional	200	100	0	0	0	0		
2. EXCESS CLAIM FE	ES					Fee (\$)	Small Entity	
Fee Description Each claim over 20	(including R	eissnes)				50	<u>Fee (\$)</u> 25	
Each independent cl	` •	•	sues)			200	100	
Multiple dependent						360	180	
Total Claims	Extra Clair	ns <u>Fee (\$)</u>	Fee Pa	aid (\$)		Multiple De	pendent Claims	
20 or HP =		_ x	_=			Fee (\$)	Fee Paid (\$)	
HP = highest number of tot Indep. Claims	al claims paid fo Extra Clair	-		: d (e)				
- 3 or HP =	EXUA CIAII	ns <u>Fee (\$)</u> x	Fee Pa	iiu (ֆ)				
HP = highest number of independent claims paid for, if greater than 3.								
3. APPLICATION SIZE FEE								
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer								
listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).								
Total Sheets								
100 = / 50 = (round up to a whole number) x =								
4. OTHER FEE(S) Non-English Specif	fication, \$1	130 fee (no sma	all entity dis	scount)			Fees Paid (\$)	
Other (e.g., late filin	ng surcharge	:): <u>Submission of</u>	an Information	on Disclosure	Statement		\$180.00	

SUBMITTED BY Registration No. (Attorney/Agent) 44,830 Telephone 858-552-2200 Signature Name (Print/Type) Mi K. Kim Date April 4, 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. APR 0 6 2005 3

PATENT Serial No. 10/629,649 Amylin Docket No.: 0212-CIP-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:)
AMYLIN PHARMACEUTICALS, INC.) Group Art Unit: 1654
Applicants: Nigel R.A. BEELEY, et al) Examiner: Jeffrey E. Russel
Serial No.: 10/629,649))
Filed: July 30, 2003))
Title: METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME)))
INFORMATION DISC	CLOSURE STATEMENT
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
Sir:	the extinue and motern decomments listed and
identified on the attached Form PTO/SB/08 are being	the articles and patent documents listed and
under 1.113, a notice of allowance under 1.311, or a	
application and is accompanied by the fee set forth in	
	formerly Form PTO-1449). Copies of the listed
references are enclosed. The Examiner is requeste	, .
record.	d to consider the references and make them of
CERTIFICATE OI (37 C.F.R. §	
I hereby certify that this paper (along with any referred to as being attached on the date shown below with sufficient postage in an envelope addressed to 22313-1450.	
	Dehorah Wykes
414105	Name of Person Mailing Paper
Date of Denosit	Signature of Person Milling Paner

04/06/2005 EAREGAY1 00000030 010535 10629649

01 FC:1806

PATENT Serial No. 10/629,649

Amylin Docket No.: 0212-CIP-9

Applicants submit that the filing of the information disclosure statement should not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b). Also enclosed is a copy of the PCT International Search Report.

A fee of \$180.00 is believed due in connection with this communication. The Commissioner is hereby authorized to charge payment of this and any additional fees associated with this communication or credit any overpayment to Amylin Pharmaceuticals, Inc.'s Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: 3/4/2005

Mi K Kin

Registration No. 44,830

AMYLIN PHARMACEUTICAL, INC.

9360 Town Centre Drive San Diego, CA 92121

Telephone: 858.552.2200 Facsimile: 858.552.1936

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patherwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known MADESIE Application Number 10/629,649 INFORMATION DISCLOSURE Filing Date July 30, 2003 STATEMENT BY APPLICANT First Named Inventor Nigel R.A. BEELEY, et al Art Unit 1646 (Use as many sheets as necessary) Examiner Name Jeffrey E. RUSSEL Sheet of 2 0212-CIP-9 Attorney Docket Number

	U.S. PATENT DOCUMENTS						
Examiner Cite		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
Examiner Cite No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear			
	1	US-6,329,403 B1	12-11-2001	ODAKA, et al.			
	2	US- 2004/0180824	09-16-2004	KNUDSEN			
•		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-	-				
		US-					
		US-					
		US-			:		
		US-					
		US-					
		US-					
		US-					

	FOREIGN PATENT DOCUMENTS						
Examiner	Examiner Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
	<u> </u>						
							

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Traistation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 14408/PTO

2

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Complete if Known				
Application Number	10/629,649			
Filing Date	July 30, 2003			
First Named Inventor	Nigel R.A. BEELEY, et al			
Art Unit	1646			
Examiner Name	Jeffrey E. Russel			
Attomey Docket Number	0212-CIP-9			

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.